Literature DB >> 33086865

18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging Detects Response to Therapeutic Intervention and Plaque Vulnerability in a Murine Model of Advanced Atherosclerotic Disease-Brief Report.

Kai-Uwe Jarr1, Jianqin Ye1, Yoko Kojima1, Vivek Nanda1,2, Alyssa M Flores1, Pavlos Tsantilas1,3, Ying Wang1, Niloufar Hosseini-Nassab4, Anne V Eberhard1, Mozhgan Lotfi1, Max Käller1, Bryan R Smith5,6, Lars Maegdefessel3,7, Nicholas J Leeper1,8,9.   

Abstract

OBJECTIVE: This study sought to determine whether 18F-fluorodeoxyglucose-positron emission tomography/computed tomography could be applied to a murine model of advanced atherosclerotic plaque vulnerability to detect response to therapeutic intervention and changes in lesion stability. Approach and
Results: To analyze plaques susceptible to rupture, we fed ApoE-/- mice a high-fat diet and induced vulnerable lesions by cast placement over the carotid artery. After 9 weeks of treatment with orthogonal therapeutic agents (including lipid-lowering and proefferocytic therapies), we assessed vascular inflammation and several features of plaque vulnerability by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and histopathology, respectively. We observed that 18F-fluorodeoxyglucose-positron emission tomography/computed tomography had the capacity to resolve histopathologically proven changes in plaque stability after treatment. Moreover, mean target-to-background ratios correlated with multiple characteristics of lesion instability, including the corrected vulnerability index.
CONCLUSIONS: These results suggest that the application of noninvasive 18F-fluorodeoxyglucose-positron emission tomography/computed tomography to a murine model can allow for the identification of vulnerable atherosclerotic plaques and their response to therapeutic intervention. This approach may prove useful as a drug discovery and prioritization method.

Entities:  

Keywords:  atherosclerosis; inflammation; mice; plaque, atherosclerotic; stroke

Mesh:

Substances:

Year:  2020        PMID: 33086865      PMCID: PMC7686289          DOI: 10.1161/ATVBAHA.120.315239

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  36 in total

1.  Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice.

Authors:  J H von der Thüsen; T J van Berkel; E A Biessen
Journal:  Circulation       Date:  2001-02-27       Impact factor: 29.690

2.  Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

Review 3.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

5.  Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.

Authors:  Fabien Hyafil; Jean-Christophe Cornily; James H F Rudd; Josef Machac; Laurent J Feldman; Zahi A Fayad
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 6.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

7.  Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis.

Authors:  Carlos Fernández-Hernando; Levente József; Deborah Jenkins; Annarita Di Lorenzo; William C Sessa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

8.  CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.

Authors:  Yoko Kojima; Jens-Peter Volkmer; Kelly McKenna; Mete Civelek; Aldons Jake Lusis; Clint L Miller; Daniel Direnzo; Vivek Nanda; Jianqin Ye; Andrew J Connolly; Eric E Schadt; Thomas Quertermous; Paola Betancur; Lars Maegdefessel; Ljubica Perisic Matic; Ulf Hedin; Irving L Weissman; Nicholas J Leeper
Journal:  Nature       Date:  2016-07-20       Impact factor: 49.962

9.  Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.

Authors:  Alyssa M Flores; Niloufar Hosseini-Nassab; Kai-Uwe Jarr; Bryan Ronain Smith; Nicholas J Leeper; Jianqin Ye; Xingjun Zhu; Robert Wirka; Ai Leen Koh; Pavlos Tsantilas; Ying Wang; Vivek Nanda; Yoko Kojima; Yitian Zeng; Mozhgan Lotfi; Robert Sinclair; Irving L Weissman; Erik Ingelsson
Journal:  Nat Nanotechnol       Date:  2020-01-27       Impact factor: 40.523

10.  Atherosclerotic Plaque Destabilization in Mice: A Comparative Study.

Authors:  Helene Hartwig; Carlos Silvestre-Roig; Jeffrey Hendrikse; Linda Beckers; Nicole Paulin; Kim Van der Heiden; Quinte Braster; Maik Drechsler; Mat J Daemen; Esther Lutgens; Oliver Soehnlein
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

View more
  3 in total

Review 1.  2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.

Authors:  Kai-Uwe Jarr; Yoko Kojima; Irving L Weissman; Nicholas J Leeper
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-04-07       Impact factor: 10.514

2.  The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis.

Authors:  Kai-Uwe Jarr; Jianqin Ye; Yoko Kojima; Zhongde Ye; Hua Gao; Sofie Schmid; Lingfeng Luo; Richard A Baylis; Mozhgan Lotfi; Nicolas Lopez; Anne V Eberhard; Bryan Ronain Smith; Irving L Weissman; Lars Maegdefessel; Nicholas J Leeper
Journal:  Nat Cardiovasc Res       Date:  2022-03-07

Review 3.  Bench-to-Bedside in Vascular Medicine: Optimizing the Translational Pipeline for Patients With Peripheral Artery Disease.

Authors:  Tom Alsaigh; Belinda A Di Bartolo; Jocelyne Mulangala; Gemma A Figtree; Nicholas J Leeper
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.